Brief: Nervgen Pharma Announces Successful End-Of-Phase 2 Meeting And FDA Alignment On Restore, A Phase 3 Registrational Study Of Nvg-291 For Chronic Tetraplegia
07/04/2026 12:45
April 7 (Reuters) - NervGen Pharma Corp NGEN.O: NERVGEN PHARMA ANNOUNCES SUCCESSFUL END-OF-PHASE 2 MEETING AND FDA ALIGNMENT ON RESTORE, A PHASE 3 REGISTRATIONAL STUDY OF NVG-291 FOR CHRONIC TETRAPLEGIA NERVGEN PHARMA CORP - RESTORE STUDY INITIATION ON-TRACK FOR MID-2026 NERVGEN PHARMA CORP - TO CONCLUDE ENROLLMENT IN PHASE 1B/2A CONNECT SCI SUBACUTE TETRAPLEGIA AND UNBLIND DATA Source text: ID:nGNXbvMn5c Further company coverage: NGEN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nervgen Pharma
See all newsBrief: Nervgen Announces First Participant Dosed In Restore, A Phase 3 Registrational Study Evaluating NVG-291 In Chronic Spinal Cord Injury
Brief: NervGen To Restate Previously Filed Financial Statements Recognizing Non-Cash Accounting Adjustments
Brief: Nervgen Reports Second Quarter 2026 Financial Results And Provides Business Updates
Brief: Nervgen Pharma Corp - Nvg-291 Shows Statistically Significant Gait Quality Improvement In Phase 1B/2A Connect Sci Study
U.S. STOCKS ON THE MOVE-Sweetgreen, Dell Technologies, Peloton Interactive